Latest Ratios: P/E Ratio -3.0x · EV/EBITDA N/A · ROE -169.2%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $122M | $36M | $76M | $4M | $318904 | $709640 | $2M | $205299 | $94880 | $407056 | $787739 |
| Enterprise Value | $119M | $33M | $64M | $3M | $-13795390 | $-4192345 | $-8858222 | $-2186701 | $-3623879 | $-5564939 | $-5798275 |
| P/E Ratio → | -3.03 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 4.37 | 1.73 | 5.23 | — | 0.03 | — | 0.16 | 0.78 | 0.05 | 0.07 | 0.12 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -169.2% | -169.2% | -332.7% | -154.9% | -253.5% | -460.9% | -706.3% | -818.3% | -217.4% | -185.4% | -141.3% |
| ROA | -127.1% | -127.1% | -178.2% | -85.1% | -135.6% | -227.2% | -464.8% | -261.7% | -144.9% | -148.7% | -113.3% |
| ROIC | -236.7% | -236.7% | — | — | — | — | — | — | — | — | — |
| ROCE | -176.3% | -176.3% | -229.2% | -129.1% | -255.6% | -453.0% | -391.3% | -730.2% | -226.9% | -185.6% | -134.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.01 | — | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.85 | — | -1.15 | — | -1.00 | -9.10 | -1.89 | -1.10 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -47.06 | -47.06 | -4.24 | -445.21 | — | -35.01 | -318.15 | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($700022)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.78 | 0.78 | 3.68 | 1.16 | 5.13 | 0.79 | 4.24 | 1.03 | 1.94 | 4.30 | 6.03 |
| Quick Ratio | 0.78 | 0.78 | 3.64 | 1.16 | 5.13 | 0.79 | 4.24 | 1.03 | 1.94 | 4.30 | 6.03 |
| Cash Ratio | 0.61 | 0.61 | 2.37 | 1.02 | 4.96 | 0.78 | 3.79 | 0.89 | 1.80 | 3.64 | 5.05 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.0% | 0.0% | — | — | — | 1.1% | 0.5% | 3.9% | 8.8% | 2.1% | 1.1% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 1.1% | 0.5% | 3.9% | 8.8% | 2.1% | 1.1% |
| Shares Outstanding | — | $48M | $19M | $752914 | $46285 | $27829 | $14791 | $5968 | $1471 | $1192 | $688 |
Includes 30+ ratios · 12 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HURA stock.
TuHURA Biosciences, Inc.'s current P/E ratio is -3.0x. This places it at the 50th percentile of its historical range.
TuHURA Biosciences, Inc.'s return on equity (ROE) is -169.2%. The historical average is -261.6%.
Based on historical data, TuHURA Biosciences, Inc. is trading at a P/E of -3.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
TuHURA Biosciences, Inc.'s current dividend yield is 0.01%.
Key Metrics
Top Statement Risk
Imminent liquidity exhaustion
Metrics are mathematically derived from official filings.
Valuation Disconnected from Operational Reality
As reported in recent financial filings, TuHURA's P/B ratio of 5.09 suggests a market valuation that appears decoupled from its underlying tangible asset base, which is heavily comprised of merger-related goodwill rather than productive capital capable of generating near-term returns for shareholders in the current biotech environment.
The absence of meaningful P/E or EV/Sales multiples reflects the company's pre-revenue status, forcing investors to rely on book value metrics that may be inflated by intangible assets. This valuation premium warrants further investigation, as it likely prices in speculative clinical success rather than the immediate, tangible risks associated with the company's precarious cash position.
Capital Decay Amidst Clinical Development
Based on the company's reported figures, ROIC has remained deeply negative, fluctuating between -32.1% and -177.2% over the last ten quarters, which indicates that the firm is currently destroying invested capital as it attempts to fund its pivotal Phase 3 clinical trial program without any offsetting revenue.
The extreme volatility in ROIC suggests that the company's capital allocation is currently dominated by non-recurring merger costs and high-burn R&D expenditures. Investors should monitor whether future clinical milestones can stabilize these returns, as the current trend suggests a persistent decay in shareholder value that is typical of late-stage oncology development.
Liquidity Constraints Threaten Operational Continuity
According to recent SEC filings, the company's current ratio has deteriorated to 1.15 as of 2026Q1, a level that appears insufficient to support the high-cost requirements of a Phase 3 registration trial, especially when compared to the more robust liquidity buffers maintained by better-capitalized immuno-oncology peers.
The rapid decline in the quick ratio over the last two years highlights a narrowing margin of safety, leaving the company vulnerable to even minor delays in clinical enrollment or regulatory timelines. This liquidity profile suggests that the firm may be forced into dilutive financing or restrictive licensing agreements to maintain its going-concern status.
Structural Disadvantage Relative to Peers
As indicated by comparative financial data, TuHURA's lack of revenue and minimal cash reserves place it at a structural disadvantage compared to peers like Iovance Biotherapeutics, which have already achieved operational milestones that provide a more stable foundation for long-term capital allocation and clinical trial execution.
While peers in the immuno-oncology space often trade at high multiples, the gap between TuHURA and its better-capitalized competitors appears to be widening due to the company's reliance on legacy merger assets. This divergence suggests that the market may be discounting HURA's potential due to the heightened risk of shareholder dilution compared to its more established industry counterparts.
Misapplication of Book Value Metrics
The P/B ratio is the most commonly misapplied metric for this business model, as it obscures the fact that the company's book value is heavily skewed by merger-related goodwill and intangible assets that provide no liquidity for the firm's ongoing, cash-intensive Phase 3 clinical trial operations.
Analysts should instead focus on the cash runway duration and the burn rate relative to clinical milestones, as these metrics provide a more accurate assessment of the company's survival probability. Relying on book value in this context may lead to an overestimation of the firm's financial flexibility and its ability to withstand further clinical delays.